Short Interest in Evotec SE (NASDAQ:EVO) Declines By 8.6%

Evotec SE (NASDAQ:EVO) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 191,400 shares, a drop of 8.6% from the August 15th total of 209,500 shares. Based on an average daily volume of 90,000 shares, the short-interest ratio is currently 2.1 days. Approximately 0.1% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EVO. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. HC Wainwright lowered their price target on shares of Evotec from $11.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Finally, Morgan Stanley lowered shares of Evotec from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $15.00 to $6.00 in a report on Monday, July 29th.

Institutional Trading of Evotec

Several hedge funds have recently bought and sold shares of the company. Quadrant Capital Group LLC bought a new stake in Evotec in the 4th quarter valued at about $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec during the 2nd quarter worth about $87,000. Cetera Advisors LLC bought a new stake in shares of Evotec during the 1st quarter worth about $188,000. DCF Advisers LLC raised its position in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after buying an additional 67,156 shares in the last quarter. Finally, Optiver Holding B.V. raised its position in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after buying an additional 69,936 shares in the last quarter. 5.81% of the stock is currently owned by institutional investors.

Evotec Stock Performance

Shares of Evotec stock remained flat at $3.64 during trading hours on Wednesday. 18,637 shares of the stock were exchanged, compared to its average volume of 105,792. The business’s 50 day moving average price is $3.88 and its 200 day moving average price is $5.20. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83. Evotec has a one year low of $2.85 and a one year high of $12.00.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.